Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS.

In this study, suvorexant acutely decreased tau phosphorylation and amyloid-β concentrations in the central nervous system. Suvorexant is approved by the Food and Drug Administration to treatment insomnia and may have potential as a repurposed drug for the prevention of Alzheimer's disease, however future studies with chronic treatment are needed. This article is protected by copyright. All rights reserved.